Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $14.16

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) gapped down prior to trading on Thursday . The stock had previously closed at $14.16, but opened at $12.81. Aligos Therapeutics shares last traded at $11.91, with a volume of 287,405 shares traded.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Aligos Therapeutics in a report on Friday.

Aligos Therapeutics Trading Down 10.2 %

The firm has a 50-day simple moving average of $13.19 and a 200-day simple moving average of $16.31. The firm has a market cap of $713.93 million, a P/E ratio of -7.14 and a beta of 2.18.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.00) by $4.75. The company had revenue of $1.06 million for the quarter. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same quarter last year, the firm earned ($10.75) EPS. Research analysts predict that Aligos Therapeutics, Inc. will post -8.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aligos Therapeutics

Several institutional investors have recently bought and sold shares of ALGS. Armistice Capital LLC lifted its holdings in shares of Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after acquiring an additional 171,490 shares in the last quarter. Opaleye Management Inc. grew its stake in shares of Aligos Therapeutics by 25.7% during the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after acquiring an additional 333,000 shares during the last quarter. Finally, Altitude Crest Partners Inc. acquired a new position in shares of Aligos Therapeutics during the fourth quarter valued at about $1,889,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).